Reem A. Assal

Heliopolis, C, Egypt

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Long non-coding RNAs in glioblastoma: from molecular drivers to therapeutic targets.

Long non-coding RNAs in glioblastoma: from molecular drivers to therapeutic targets.

Journal: Frontiers in immunology
Published: May 21, 2026

Urolithin A counteracts cyclophosphamide-induced chemobrain in rats through modulation of mitochondrial signaling pathways.

Urolithin A counteracts cyclophosphamide-induced chemobrain in rats through modulation of mitochondrial signaling pathways.

Journal: Journal of ethnopharmacology
Published: December 20, 2025

Editorial: Regulators of the immune-tumor microenvironment: a new frontier for cancer immunotherapy.

Editorial: Regulators of the immune-tumor microenvironment: a new frontier for cancer immunotherapy.

Journal: Frontiers in medicine
Published: December 10, 2025

Maternally Expressed Gene 3 (MEG3) LncRNA: The silent guardian against solid and hematological malignancies.

Maternally Expressed Gene 3 (MEG3) LncRNA: The silent guardian against solid and hematological malignancies.

Journal: Critical reviews in oncology/hematology
Published: August 19, 2025

Macrophage migration inhibitory factor (MIF) and the tumor ecosystem: a tale of inflammation, immune escape, and tumor growth.

Macrophage migration inhibitory factor (MIF) and the tumor ecosystem: a tale of inflammation, immune escape, and tumor growth.

Journal: Frontiers in immunology
Published: May 28, 2025

Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers.

Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers.

Journal: Frontiers in oncology
Published: October 29, 2024

miR-17-5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients.

miR-17-5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients.

Journal: Pathology, research and practice
Published: August 04, 2024

OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma.

OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma.

Journal: BMC gastroenterology
Published: June 09, 2024

N-[4-(Benzyloxy)-3-methoxybenzyl)]adamantane-1-amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer.

N-[4-(Benzyloxy)-3-methoxybenzyl)]adamantane-1-amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer.

Journal: Archiv der Pharmazie
Published: February 24, 2024

A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.

A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.

Journal: Translational oncology
Published: February 04, 2024

Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies.

Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies.

Journal: Pathology, research and practice
Published: January 05, 2024

Editorial: Understanding the crosstalk between immune cells and the tumor microenvironment in cancer and its implications for immunotherapy.

Editorial: Understanding the crosstalk between immune cells and the tumor microenvironment in cancer and its implications for immunotherapy.

Journal: Frontiers in medicine
Published: April 08, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026